JP2023500060A5 - - Google Patents

Info

Publication number
JP2023500060A5
JP2023500060A5 JP2022523485A JP2022523485A JP2023500060A5 JP 2023500060 A5 JP2023500060 A5 JP 2023500060A5 JP 2022523485 A JP2022523485 A JP 2022523485A JP 2022523485 A JP2022523485 A JP 2022523485A JP 2023500060 A5 JP2023500060 A5 JP 2023500060A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
treatment
compound
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500060A (ja
JP7594004B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/079802 external-priority patent/WO2021078889A1/en
Publication of JP2023500060A publication Critical patent/JP2023500060A/ja
Publication of JP2023500060A5 publication Critical patent/JP2023500060A5/ja
Application granted granted Critical
Publication of JP7594004B2 publication Critical patent/JP7594004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523485A 2019-10-22 2020-10-22 フェロポーチン阻害剤(vit-2763)を用いる鎌状赤血球症を治療するための方法及び組成物 Active JP7594004B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924556P 2019-10-22 2019-10-22
EP19000483 2019-10-22
US62/924,556 2019-10-22
EP19000483.8 2019-10-22
EP20163777 2020-03-17
EP20163777.4 2020-03-17
EP20176336.4 2020-05-25
EP20176336 2020-05-25
PCT/EP2020/079802 WO2021078889A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)

Publications (3)

Publication Number Publication Date
JP2023500060A JP2023500060A (ja) 2023-01-04
JP2023500060A5 true JP2023500060A5 (cg-RX-API-DMAC7.html) 2023-06-06
JP7594004B2 JP7594004B2 (ja) 2024-12-03

Family

ID=73005635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523485A Active JP7594004B2 (ja) 2019-10-22 2020-10-22 フェロポーチン阻害剤(vit-2763)を用いる鎌状赤血球症を治療するための方法及び組成物

Country Status (11)

Country Link
US (1) US20220274973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048262A1 (cg-RX-API-DMAC7.html)
JP (1) JP7594004B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220086563A (cg-RX-API-DMAC7.html)
CN (1) CN114765955B (cg-RX-API-DMAC7.html)
AU (1) AU2020369137A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154524A1 (cg-RX-API-DMAC7.html)
IL (1) IL291137A (cg-RX-API-DMAC7.html)
MX (1) MX2022004806A (cg-RX-API-DMAC7.html)
WO (1) WO2021078889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536683A4 (en) * 2022-06-07 2026-06-10 Protagonist Therapeutics Inc HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE
WO2024083980A1 (en) 2022-10-21 2024-04-25 Vifor (International) Ag Bicyclic ferroportin inhibitors
CN121511085A (zh) 2023-06-26 2026-02-10 威佛(国际)股份公司 用于遗传性血色素沉着病(hh)的治疗的膜铁转运蛋白抑制剂
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis
WO2026120152A1 (en) 2024-12-06 2026-06-11 Vifor (International) Ag Prolonged-release dosage forms of ferroportin inhibitors for use in treating hereditary haemochromatosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Similar Documents

Publication Publication Date Title
JP7660600B2 (ja) 慢性炎症性疾患および/または自己免疫疾患の予防または治療における使用のためのビドフルジムス(Vidofludimus)の投与レジメン
EP2222314B1 (en) Uses and means for otaining bronchorelaxation
TW200520762A (en) Compositions and methods for topical treatment of skin infection
CN107519159A (zh) 复方组合物
WO2007001961A2 (en) Method for the treatment of acne
FI4426298T3 (fi) Uusia terapeuttisia yhdistelmiä, jotka käsittävät pirfenidonia ja pde4-estäjää, etenevien fibrosoivien interstitiaalisten keuhkosairauksien hoitamiseksi
TW202617156A (zh) 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法
US20170319519A1 (en) Combination for the treatment of conditions involving muscular pain
CA2206995C (en) Use of alkanoyl l-carnitines for the therapeutical treatment of chronic inflammatory bowel diseases
WO2020055226A1 (es) Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona
HRP20241621T1 (hr) (1r,3s)-3-((5-cijano-4-feniltiazol-2-il)karbamoil)ciklopentan-1-karboksilna kiselina, namijenjena upotrebi u liječenju bolesti dišnih puteva
JP2023538419A5 (cg-RX-API-DMAC7.html)
JP2022518288A5 (cg-RX-API-DMAC7.html)
US4175128A (en) Method for treating congestive heart failure
WO2004017973A1 (ja) 統合失調症治療剤
JP6188784B2 (ja) 炎症性および免疫性疾患の治療のための組成物
Poole-Wilson Timolol maleate (MK 950) in the treatment of essential hypertension
AU2024203992B2 (en) Prophylactic or therapeutic agent for porphyria
GB2240472A (en) Agent for use in the prevention, control or reversal of hypertension
CN117243948A (zh) 包含瑞香素的组合物在制备风湿性关节炎药物中的应用
WO2025103426A1 (zh) 白塞综合征的治疗
JPS61200917A (ja) ベタキソロールとニフエジピンとを含有する医薬組成物
BR112019009859A2 (pt) composições para o tratamento da hipertensão
HK1207293B (en) Composition for the treatment of inflammatory and immune disorders